2303, 2015

CIS Pharma appoints Davide Panighetti to its cancer research team

Bubendorf, Switzerland, Monday, March 23, 2015 - CIS Pharma welcomes Davide Panighetti, who reinforces the research team as a new synthesis chemist. Davide’s skills will boost the team working on proprietary polymer-drug carrier developed for antibody-drug conjugates and antibody-radionuclide conjugates. The polymer-drug carriers are based on the CIS Pharma's proprietary polymer technology allowing ADCs to be custom designed for delivery [...]

1102, 2015

CIS Pharma team attends Pharmapack 2015 in Paris

Paris, France, Wednesday to Thursday, February 11 to 12, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

1201, 2015

CIS Pharma to develop drug carriers for ADCs

Bubendorf, Switzerland, Monday, January 12, 2015 - CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared [...]

1210, 2014

CIS Pharma signs development and licensing agreement with marketing partner for cefuroxime

Bubendorf, Switzerland, October 12, 2014 – CIS Pharma signs development and licensing agreement with licensee. Having developed intracameral cefuroxime as a response to the clinical demand for such a product, CIS Pharma is proud to have signed a deal on the regulatory approval and distribution of its product. Also, the deal includes a license to CIS Pharma’s patent protected cefuroxime [...]